Investors who own more than 5% of a class must file a Schedule 13D or 13G. Every filing since 12/18/2024, newest first.
| Issuer | % of Class | Filed | |||
|---|---|---|---|---|---|
|
Electra Therapeutics, Inc.
13G
284825106
|
8.7% |
9/28/2026
Event 9/21/2026
|
|||
| Redmile Group, LLC | 8.7% | ||||
| Jeremy C. Green | 8.7% | ||||
| Redmile Biopharma Investments II, L.P. | 7.6% | ||||
|
Nurix Therapeutics, Inc.
13G/A
Amendment 6
NRIX · 67080M103
|
8.1%
Checked 5% or less
|
8/14/2026
Event 6/30/2026
|
|||
| Redmile Group, LLC | 8.1% | ||||
| Jeremy C. Green | 8.1% | ||||
| RedCo II Offshore SPV LLC | 3.5% | ||||
|
Neurogene Inc.
13G/A
Amendment 7
NGNE · 64135M105
|
9.9% |
8/14/2026
Event 6/30/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments I, L.P. | 5.1% | ||||
|
Scholar Rock Holding Corporation
13G/A
Amendment 11
SRRK · 80706P103
|
3.6% |
8/14/2026
Event 6/30/2026
|
|||
| Redmile Group, LLC | 3.6% | ||||
| Jeremy C. Green | 3.6% | ||||
| RedCo II Master Fund, L.P. | 0% | ||||
|
Atara Biotherapeutics, Inc.
13D/A
Amendment 3
ATRA · 046513206
|
9.9% |
7/24/2026
Event 7/22/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Green Jeremy | 9.9% | ||||
| Redmile Biopharma Investments II, L.P. | 6.6% | ||||
| Redmile Strategic Long Only Trading Sub, Ltd. | 4.2% | ||||
|
Shattuck Labs, Inc.
13D/A
Amendment 6
STTK · 82024L103
|
9.9% |
7/17/2026
Event 7/15/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments II, L.P. | 8.1% | ||||
|
Annexon, Inc.
13G/A
Amendment 6
ANNX · 03589W102
|
9.9% |
7/8/2026
Event 7/1/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| RedCo II Offshore SPV LLC | 5.5% | ||||
|
Shattuck Labs, Inc.
13D/A
Amendment 5
STTK · 82024L103
|
9.9% |
6/11/2026
Event 6/9/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments II, L.P. | 6.2% | ||||
|
AgomAb Therapeutics NV
13G
AGMB · 00860C102
|
5.6% |
5/15/2026
Event 3/31/2026
|
|||
| Redmile Group, LLC | 5.6% | ||||
| Jeremy C. Green | 5.6% | ||||
| Redmile Biopharma Investments III, L.P. | 5.6% | ||||
|
Scholar Rock Holding Corporation
13G/A
Amendment 10
SRRK · 80706P103
|
7.6% |
5/15/2026
Event 3/31/2026
|
|||
| Redmile Group, LLC | 7.6% | ||||
| Jeremy C. Green | 7.6% | ||||
| RedCo II Master Fund, L.P. | 5.8% | ||||
|
Stoke Therapeutics, Inc.
13G/A
Amendment 6
STOK · 86150R107
|
6.7% |
5/15/2026
Event 3/31/2026
|
|||
| Redmile Group, LLC | 6.7% | ||||
| Jeremy C. Green | 6.7% | ||||
| Redmile Biopharma Investments III, L.P. | 5.6% | ||||
|
Immunome, Inc.
13G/A
Amendment 4
IMNM · 45257U108
|
4.9% |
5/15/2026
Event 3/31/2026
|
|||
| Redmile Group, LLC | 4.9% | ||||
| Jeremy C. Green | 4.9% | ||||
|
ALX Oncology Holdings Inc.
13G/A
Amendment 3
ALXO · 00166B105
|
6.8%
Checked 5% or less
|
5/15/2026
Event 3/31/2026
|
|||
| Redmile Group, LLC | 6.8% | ||||
| Jeremy C. Green | 6.8% | ||||
| Redmile Biopharma Investments III, L.P. | 3.9% | ||||
|
Atara Biotherapeutics, Inc.
13D/A
Amendment 2
ATRA · 046513206
|
9.9% |
5/14/2026
Event 5/12/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments II, L.P. | 6.9% | ||||
| Redmile Strategic Long Only Trading Sub, Ltd. | 6.1% | ||||
|
ADC Therapeutics SA
13G/A
Amendment 8
ADCT · H0036K147
|
9.9%
Checked 5% or less
|
4/24/2026
Event 4/20/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| RedCo II Offshore SPV LLC | 6.1% | ||||
| RedCo II Master Fund, L.P. | 0% | ||||
|
Nurix Therapeutics, Inc.
13G/A
Amendment 5
NRIX · 67080M103
|
9.9%
Checked 5% or less
|
4/24/2026
Event 4/20/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| RedCo II Offshore SPV LLC | 5.6% | ||||
| RedCo II Master Fund, L.P. | 0% | ||||
|
Fate Therapeutics Inc
13D/A
Amendment 10
FATE · 31189P102
|
14.9% |
4/22/2026
Event 4/20/2026
|
|||
| Redmile Group, LLC | 14.9% | ||||
| Jeremy C. Green | 14.9% | ||||
| RedCo II Offshore SPV LLC | 8.5% | ||||
| RedCo II Master Fund, L.P. | 0% | ||||
|
Absci Corporation
13D/A
Amendment 4
ABSI · 00091E109
|
4.9% |
4/14/2026
Event 4/10/2026
|
|||
| Redmile Group, LLC | 4.9% | ||||
| Jeremy C. Green | 4.9% | ||||
|
ADC Therapeutics SA
13G/A
Amendment 7
ADCT · H0036K147
|
9.9% |
4/6/2026
Event 4/6/2026
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| RedCo II Master Fund, L.P. | 8.1% | ||||
|
Absci Corporation
13D/A
Amendment 3
ABSI · 00091E109
|
5.4% |
3/26/2026
Event 3/24/2026
|
|||
| Redmile Group, LLC | 5.4% | ||||
| Jeremy C. Green | 5.4% | ||||
|
Neurogene Inc.
13G/A
Amendment 6
NGNE · 64135M105
|
9.9%
Checked 5% or less
|
2/17/2026
Event 12/31/2025
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments I, L.P. | 4.8% | ||||
|
Immunome, Inc.
13G/A
Amendment 3
IMNM · 45257U108
|
5.2% |
2/17/2026
Event 12/31/2025
|
|||
| Redmile Group, LLC | 5.2% | ||||
| Jeremy C. Green | 5.2% | ||||
|
Annexon, Inc.
13G/A
Amendment 5
ANNX · 03589W102
|
9.9%
Checked 5% or less
|
2/17/2026
Event 12/31/2025
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments II, L.P. | 4.7% | ||||
|
ADC Therapeutics SA
13G/A
Amendment 6
ADCT · H0036K147
|
12.7% |
2/17/2026
Event 12/31/2025
|
|||
| Redmile Group, LLC | 12.7% | ||||
| Jeremy C. Green | 12.7% | ||||
| RedCo II Master Fund, L.P. | 10.6% | ||||
|
Atara Biotherapeutics, Inc.
13D/A
Amendment 1
ATRA · 046513206
|
9.9% |
11/14/2025
Event 11/12/2025
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| RedCo I, L.P. | 4.7% | ||||
| Redmile Biopharma Investments II, L.P. | 6.0% | ||||
| Redmile Strategic Long Only Trading Sub, Ltd. | 5.0% | ||||
|
Zymeworks Inc.
13G/A
Amendment 6
ZYME · 98985Y108
|
4.9% |
11/14/2025
Event 9/30/2025
|
|||
| Redmile Group, LLC | 4.9% | ||||
| Jeremy C. Green | 4.9% | ||||
|
Replimune Group, Inc.
13G/A
Amendment 9
REPL · 76029N106
|
0.7% |
11/14/2025
Event 9/30/2025
|
|||
| Redmile Group, LLC | 0.7% | ||||
| Jeremy C. Green | 0.7% | ||||
|
Shattuck Labs, Inc.
13D/A
Amendment 4
STTK · 82024L103
|
9.9% |
8/26/2025
Event 8/25/2025
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments II, L.P. | 6.4% | ||||
|
IGM Biosciences, Inc.
13D/A
Amendment 7
IGMS · 449585108
|
0% |
8/15/2025
Event 8/14/2025
|
|||
| Redmile Group, LLC | 0% | ||||
| Jeremy C. Green | 0% | ||||
|
Zymeworks Inc.
13G/A
Amendment 5
ZYME · 98985Y108
|
5.6%
Checked 5% or less
|
8/14/2025
Event 6/30/2025
|
|||
| Redmile Group, LLC | 5.6% | ||||
| Jeremy C. Green | 5.6% | ||||
| Redmile Biopharma Investments III, L.P. | 4.6% | ||||
|
Stoke Therapeutics, Inc.
13G/A
Amendment 5
STOK · 86150R107
|
8.0% |
8/14/2025
Event 6/30/2025
|
|||
| Redmile Group, LLC | 8.0% | ||||
| Jeremy C. Green | 8.0% | ||||
| Redmile Biopharma Investments III, L.P. | 6.4% | ||||
|
REGENXBIO Inc.
13G/A
Amendment 3
RGNX · 75901B107
|
9.9% |
8/14/2025
Event 6/30/2025
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments III, L.P. | 7.4% | ||||
|
RAPT Therapeutics, Inc.
13G/A
Amendment 4
RAPT · 75382E208
|
9.9% |
8/14/2025
Event 6/30/2025
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments III, L.P. | 6.5% | ||||
|
ALX Oncology Holdings Inc.
13G/A
Amendment 2
ALXO · 00166B105
|
8.5% |
8/14/2025
Event 6/30/2025
|
|||
| Redmile Group, LLC | 8.5% | ||||
| Jeremy C. Green | 8.5% | ||||
| Redmile Biopharma Investments III, L.P. | 6.7% | ||||
|
ADC Therapeutics SA
13G/A
Amendment 5
ADCT · H0036K147
|
14.0% |
8/14/2025
Event 6/30/2025
|
|||
| Redmile Group, LLC | 14.0% | ||||
| Jeremy C. Green | 14.0% | ||||
| RedCo II Master Fund, L.P. | 11.7% | ||||
|
Shattuck Labs, Inc.
13D/A
Amendment 3
STTK · 82024L103
|
11.8% |
8/6/2025
Event 8/4/2025
|
|||
| Redmile Group, LLC | 11.8% | ||||
| Jeremy C. Green | 11.8% | ||||
| Redmile Biopharma Investments II, L.P. | 7.0% | ||||
|
Fate Therapeutics Inc
13D/A
Amendment 9
FATE · 31189P102
|
14.9% |
7/3/2025
Event 7/2/2025
|
|||
| Redmile Group, LLC | 14.9% | ||||
| Jeremy C. Green | 14.9% | ||||
| RedCo II Master Fund, L.P. | 11.3% | ||||
|
Atara Biotherapeutics, Inc.
13D
ATRA · 046513206
|
9.9% |
5/23/2025
Event 5/16/2025
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| RedCo I, L.P. | 5.0% | ||||
| Redmile Biopharma Investments II, L.P. | 5.8% | ||||
|
Silence Therapeutics plc
13G/A
Amendment 1
G8128Y157
|
4.7% |
5/15/2025
Event 3/31/2025
|
|||
| Redmile Group, LLC | 4.7% | ||||
| Jeremy C. Green | 4.7% | ||||
|
Replimune Group, Inc.
13G/A
Amendment 8
REPL · 76029N106
|
6.4% |
5/15/2025
Event 3/31/2025
|
|||
| Redmile Group, LLC | 6.4% | ||||
| Jeremy C. Green | 6.4% | ||||
|
Immunome, Inc.
13G/A
Amendment 2
IMNM · 45257U108
|
6.2%
Checked 5% or less
|
5/15/2025
Event 3/31/2025
|
|||
| Redmile Group, LLC | 6.2% | ||||
| Jeremy C. Green | 6.2% | ||||
| Redmile Biopharma Investments III, L.P. | 4.5% | ||||
|
Atara Biotherapeutics, Inc.
13G/A
Amendment 10
ATRA · 046513206
|
9.9% |
5/15/2025
Event 3/31/2025
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| RedCo I, L.P. | 5.8% | ||||
| Redmile Biopharma Investments II, L.P. | 5.0% | ||||
|
Absci Corporation
13D/A
Amendment 2
ABSI · 00091E109
|
6.5% |
4/29/2025
Event 4/25/2025
|
|||
| Redmile Group, LLC | 6.5% | ||||
| Jeremy C. Green | 6.5% | ||||
| Redmile Biopharma Investments II, L.P. | 4.9% | ||||
|
Zymeworks Inc.
13G/A
Amendment 4
ZYME · 98985Y108
|
7.0% |
2/14/2025
Event 12/31/2024
|
|||
| Redmile Group, LLC | 7.0% | ||||
| Jeremy C. Green | 7.0% | ||||
| Redmile Biopharma Investments III, L.P. | 5.0% | ||||
|
Silence Therapeutics plc
13G
G8128Y157
|
5.1% |
2/14/2025
Event 12/31/2024
|
|||
| Redmile Group, LLC | 5.1% | ||||
| Jeremy C. Green | 5.1% | ||||
|
Scholar Rock Holding Corporation
13G/A
Amendment 9
SRRK · 80706P103
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| RedCo II Master Fund, L.P. | 6.9% | ||||
|
RAPT Therapeutics, Inc.
13G/A
Amendment 3
RAPT · 75382E109
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments III, L.P. | 5.4% | ||||
|
Pliant Therapeutics, Inc.
13G/A
Amendment 1
PLRX · 729139105
|
4.8% |
2/14/2025
Event 12/31/2024
|
|||
| Redmile Group, LLC | 4.8% | ||||
| Jeremy C. Green | 4.8% | ||||
|
Neurogene Inc.
13G/A
Amendment 5
NGNE · 64135M105
|
9.9% |
2/14/2025
Event 12/31/2024
|
|||
| Redmile Group, LLC | 9.9% | ||||
| Jeremy C. Green | 9.9% | ||||
| Redmile Biopharma Investments I, L.P. | 5.4% | ||||
|
Gritstone bio, Inc.
13G/A
Amendment 8
GRTSQ · 39868T105
|
8.2%
Checked 5% or less
|
2/14/2025
Event 12/31/2024
|
|||
| Redmile Group, LLC | 8.2% | ||||
| Jeremy C. Green | 8.2% | ||||
| RedCo II Master Fund, L.P. | 4.7% | ||||
|
Amicus Therapeutics, Inc.
13G/A
Amendment 13
FOLD · 03152W109
|
4.6% |
2/14/2025
Event 12/31/2024
|
|||
| Redmile Group, LLC | 4.6% | ||||
| Jeremy C. Green | 4.6% | ||||
|
Fate Therapeutics Inc
13D/A
Amendment 8
FATE · 31189P102
|
14.9% |
12/26/2024
Event 12/20/2024
|
|||
| Redmile Group, LLC | 14.9% | ||||
| Jeremy C. Green | 14.9% | ||||
| RedCo II Master Fund, L.P. | 8.5% | ||||